Defining valuable information in a shifting industry

Authors

  • Andrew F Bourgoin Thomson Reuters

DOI:

https://doi.org/10.5912/jcb606

Keywords:

pharmaceuticals, biologics, generics, biosimilars

Author Biography

Andrew F Bourgoin, Thomson Reuters

Andrew Fischer Bourgoin is a Senior Pharmaceutical Research Analyst - Biologcs at Thomson Reuters (TR), the world’s leading information provider and global media company. In this role, Andrew is responsible for collecting and validating the intelligence contained in the Newport product suite that focuses on developments within the global biologic pharmaceutical landscape.

References

Reuters Factbox. (2010) World’s top-selling drugs in 2014 vs 2010. http://www.reuters.com/article/2010/04/13/roche-avastin-drugs-idUSLDE63C0BC20100413

Generic Pharmaceutical Association. (2012) Generic Drug Savings. http://www.gphaonline.org/sites/default/files/IMS%20Study%20Aug%202012%20WEB.pdf

Downloads

Published

2013-04-01

Issue

Vol. 19 No. 2 (2013)

Section

Commentary